Goldman Sachs’s Dynavax Technologies DVAX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-42,200
| Closed | -$649K | – | 6611 |
|
|
2025
Q4 | $649K | Sell |
42,200
-202,700
| -83% | -$2.23M | ﹤0.01% | 5436 |
|
|
2025
Q3 | $2.43M | Buy |
+244,900
| New | +$2.55M | ﹤0.01% | 4303 |
|
|
2025
Q2 | – | Sell |
-49,900
| Closed | -$647K | – | 6157 |
|
|
2025
Q1 | $647K | Sell |
49,900
-151,800
| -75% | -$2.01M | ﹤0.01% | 5023 |
|
|
2024
Q4 | $2.58M | Buy |
201,700
+155,000
| +332% | +$1.87M | ﹤0.01% | 4067 |
|
|
2024
Q3 | $520K | Buy |
+46,700
| New | +$515K | ﹤0.01% | 5028 |
|
|
2024
Q2 | – | Sell |
-20,100
| Closed | -$249K | – | 5708 |
|
|
2024
Q1 | $249K | Buy |
+20,100
| New | +$262K | ﹤0.01% | 5036 |
|
|
2022
Q1 | – | Sell |
-30,900
| Closed | -$435K | – | 6631 |
|
|
2021
Q4 | $435K | Hold |
30,900
| – | – | ﹤0.01% | 5463 |
|
|
2021
Q3 | $594K | Hold |
30,900
| – | – | ﹤0.01% | 5095 |
|
|
2021
Q2 | $304K | Hold |
30,900
| – | – | ﹤0.01% | 5516 |
|
|
2021
Q1 | $304K | Buy |
+30,900
| New | +$255K | ﹤0.01% | 5425 |
|
|
2017
Q4 | – | Sell |
-92,700
| Closed | -$1.99M | – | 6405 |
|
|
2017
Q3 | $1.99M | Buy |
+92,700
| New | +$1.47M | ﹤0.01% | 3996 |
|
|
2017
Q1 | – | Sell |
-50,000
| Closed | -$198K | – | 6809 |
|
|
2016
Q4 | $198K | Hold |
50,000
| – | – | ﹤0.01% | 5775 |
|
|
2016
Q3 | $525K | Buy |
50,000
+39,400
| +372% | +$566K | ﹤0.01% | 4995 |
|
|
2016
Q2 | $155K | Buy |
+10,600
| New | +$181K | ﹤0.01% | 5866 |
|
|
2015
Q3 | – | Sell |
-11,000
| Closed | -$258K | – | 7317 |
|
|
2015
Q2 | $258K | Buy |
+11,000
| New | +$240K | ﹤0.01% | 5897 |
|
Other funds holding DVAX
Goldman Sachs's DVAX Position: Q1 2026 in Review
Goldman Sachs sold out of Dynavax Technologies (DVAX) in Q1 2026, closing a stake of 2,153,979 shares — an estimated $33.1M sold.
Goldman Sachs first reported a position in DVAX in Q2 2013 and held it in 50 quarters. The position peaked at $53.4M in Q2 2024. 1 fund tracked by Wall St. Rank holds DVAX as of Q1 2026.
- Goldman Sachs reported no remaining Dynavax Technologies position as of Q1 2026 after selling out during the quarter.
- Goldman Sachs sold 2,153,979 Dynavax Technologies shares in Q1 2026, an estimated $33.1M.
- Goldman Sachs first reported a position in Dynavax Technologies in Q2 2013 and held it in 50 quarters.
- Goldman Sachs's Dynavax Technologies position peaked at $53.4M in Q2 2024.
- 1 fund tracked by Wall St. Rank held Dynavax Technologies as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.